25 March 2024
ImmuPharma PLC
("ImmuPharma" or the
"Company")
Incanthera Provides Commercial Update
and
Revenue Forecasts
ImmuPharma PLC (LSE AIM: IMM), the
specialist drug discovery and development company, is delighted to
highlight the announcement issued this morning by Incanthera plc
("Incanthera"), the dermatology and oncology specialist, in which
ImmuPharma currently holds a 10.8% shareholding.
Within the announcement, Incanthera
announces an update on its commercial
skincare deal, announced in December 2023, with Marionnaud (part of
the A.S. Watson Group).
Under the terms of the deal, Skin +
CELL will be initially launched in c. 100 of Marionnaud's stores
in Switzerland and Austria, followed by a planned
roll out into the remaining 1,100 European stores, with subsequent
anticipated roll outs into major Asian markets.
Incanthera has announced that the
first order from Marionnaud has now doubled from 25,000 units to
50,000 units due to the strong demand anticipated by Marionnaud's
management and that this first order, on track to be delivered
during Q2 2024, will generate c. £2m revenue for
Incanthera.
Incanthera also confirms that
it projects revenues of £10m and
profitability, for the financial year ("FY") to 31 March 2025,
growing to revenues of £33m and increased profitability, in the
following FY to 31 March 2026.
More insight into Incanthera's
technology and deal with Marionnaud is illustrated through the
initiation of a Research Note by Stanford Capital Partners, which
will shortly be available on the Incanthera plc website
www.incanthera.com.
Incanthera trades on Aquis Stock
Exchange ("AQSE") under the ticker (AQSE:INC). For full details of the announcement, please visit
Incanthera's website: https://incanthera.com/investors/regulatory-news/.
Commenting on Incanthera's announcement, Dr Tim Franklin, COO
of ImmuPharma said: "As a major shareholder in Incanthera, we are
delighted with this further progress and in particular Incanthera's
revenue momentum and move into profitability. This highlights the
strong financial asset we have in Incanthera and the enormous
opportunities within the company's revolutionary skincare range and
its partnership with Marionnaud."
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.com)
Dr Tim Franklin, COO
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 203 650 3650/51
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140 (Lupuzor™), is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases
that share the same autophagy mechanism of action.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
Incanthera originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on Incanthera
please visit: www.incanthera.com